NEW YORK (GenomeWeb) – Illumina reported after the close of the market Tuesday that its first quarter revenues increased 27 percent year over year.

The San Diego-based firm posted revenues of $421 million for the three months ended March 31, compared to $331 million for the first quarter of 2012. It beat the average analyst estimate of $391.8 million.

Its product revenue jumped to $362.2 million from $296.2 million year over year, and its service and other revenue increased to $58.6 million from $34.8 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.